160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I

S. Ponce Aix,E. Carcereny Costa,J. Bosch-Barrera, E. Felip Font, M. Guirado,J. Coves Sarto,M. Majem Tarruella, O.J. Juan Vidal, E. Dalmau Portulas, P. Diz,A.L.O. Ortega Granados,M. Domine Gomez,A. Blasco Cordellat,J. Mosquera Martinez,M.A. Sala Gonzalez, M. Dorta,V. Calvo de Juan, J. Zugazagoitia, A.B. Enguita, L. Paz-Ares

Annals of Oncology（2021）

引用 2|浏览4

暂无评分

摘要

Current front-line treatment for NSCLC includes PD1/PDL1 checkpoint inhibitors (CPI) alone or in combination with chemotherapy. Second line treatment approach is an unmet need, mainly limited to Docetaxel, and the utility of CPI is an open question. Here we report preliminary data of cohort 1 of the REPLAY trial that assess the efficacy of pembrolizumab (pembro) re-challenge.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要